| Tbio | Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 |
Functional component of the Nogo receptor signaling complex (RTN4R/NGFR) in RhoA activation responsible for some inhibition of axonal regeneration by myelin-associated factors (PubMed:14966521, PubMed:15694321). Is also an important negative regulator of oligodentrocyte differentiation and axonal myelination (PubMed:15895088). Acts in conjunction with RTN4 and RTN4R in regulating neuronal precursor cell motility during cortical development (By similarity).
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Essential tremor | 28 | 6.587 | 3.3 |
| Disease | Target Count | P-value |
|---|---|---|
| astrocytoma | 1146 | 1.5e-09 |
| atypical teratoid / rhabdoid tumor | 5112 | 1.6e-07 |
| group 4 medulloblastoma | 1855 | 1.1e-05 |
| ependymoma | 4679 | 4.3e-04 |
| adult high grade glioma | 3801 | 2.7e-03 |
| medulloblastoma, large-cell | 6241 | 5.2e-03 |
| glioblastoma | 5792 | 7.6e-03 |
| invasive ductal carcinoma | 2951 | 1.3e-02 |
| inflammatory breast cancer | 286 | 3.7e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Disseminated intravascular coagulation | 38 | 0.0 | 0.9 |
| Movement disease | 11 | 0.0 | 3.0 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Multiple Sclerosis | 540 | 4.412 | 2.2 |
| Optic neuritis | 5 | 3.61 | 1.8 |
| Parkinson's disease | 392 | 3.422 | 1.7 |
| Disease | log2 FC | p |
|---|---|---|
| adult high grade glioma | -1.600 | 2.7e-03 |
| astrocytoma | -1.200 | 1.5e-09 |
| atypical teratoid / rhabdoid tumor | -2.600 | 1.6e-07 |
| ependymoma | -1.400 | 4.3e-04 |
| glioblastoma | -1.300 | 7.6e-03 |
| group 4 medulloblastoma | -2.200 | 1.1e-05 |
| inflammatory breast cancer | 1.100 | 3.7e-02 |
| invasive ductal carcinoma | 1.200 | 1.3e-02 |
| medulloblastoma, large-cell | -2.300 | 5.2e-03 |
MQVSKRMLAGGVRSMPSPLLACWQPILLLVLGSVLSGSATGCPPRCECSAQDRAVLCHRKRFVAVPEGIP 1 - 70 TETRLLDLGKNRIKTLNQDEFASFPHLEELELNENIVSAVEPGAFNNLFNLRTLGLRSNRLKLIPLGVFT 71 - 140 GLSNLTKLDISENKIVILLDYMFQDLYNLKSLEVGDNDLVYISHRAFSGLNSLEQLTLEKCNLTSIPTEA 141 - 210 LSHLHGLIVLRLRHLNINAIRDYSFKRLYRLKVLEISHWPYLDTMTPNCLYGLNLTSLSITHCNLTAVPY 211 - 280 LAVRHLVYLRFLNLSYNPISTIEGSMLHELLRLQEIQLVGGQLAVVEPYAFRGLNYLRVLNVSGNQLTTL 281 - 350 EESVFHSVGNLETLILDSNPLACDCRLLWVFRRRWRLNFNRQQPTCATPEFVQGKEFKDFPDVLLPNYFT 351 - 420 CRRARIRDRKAQQVFVDEGHTVQFVCRADGDPPPAILWLSPRKHLVSAKSNGRLTVFPDGTLEVRYAQVQ 421 - 490 DNGTYLCIAANAGGNDSMPAHLHVRSYSPDWPHQPNKTFAFISNQPGEGEANSTRATVPFPFDIKTLIIA 491 - 560 TTMGFISFLGVVLFCLVLLFLWSRGKGNTKHNIEIEYVPRKSDAGISSADAPRKFNMKMI 561 - 620 //
